We have identified CUDC-907, a potent dual inhibitor targeting both PI3K and HDAC, and currently under clinical trials for B cell lymphoma, as a promising therapeutic for MEF2D fusion-expressing BCP-ALL. Here, MEF2D is linked to acute lymphoblastic leukemia.